BM7PE

BM7PE is an antibody-drug conjugate (ADC) composed of the murine monoclonal antibody BM7, which targets the human tumor-associated antigen mucin-1 (MUC1), covalently linked to pseudomonas exotoxin A (PE). The mechanism of action involves specific binding to MUC1-expressing tumor cells, followed by internalization and delivery of the cytotoxic PE payload, leading to inhibition of protein synthesis and cell death. Developed by Oslo universitetssykehus HF (Oslo University Hospital), it is being investigated primarily for metastatic colorectal carcinoma in patients refractory or intolerant to standard chemotherapy. Preclinical studies have also demonstrated activity against breast cancer models[1][2][6][8].

Other names

anti-mucin-1/PE immunoconjugate BM7PE